Appoints Giancarlo Benelli as Head of Europe at BeiGene
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company set to rebrand as BeOne Medicines Ltd., appoints Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1st. This appointment underscores the company’s dedication to expanding access to transformative medicines for patients across Europe. The company appoints Mr. Benelli to this strategic role as part of its continued transformation, positioning itself to strengthen its presence in Europe and beyond.
This appointment marks a significant milestone in BeiGene’s ongoing transformation, as it appoints new leadership to drive its growth in the European market. The company is committed to expanding its reach and impact in the fight against cancer, and this leadership change reflects its efforts to solidify its position as a top global oncology innovator. Mr. Benelli will be based at the company’s office in Basel, Switzerland, which will serve as a critical hub for BeiGene’s growing operations across the continent. By appointing him to lead this important region, BeiGene seeks to enhance its ability to bring innovative treatments to more patients in Europe.
John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene, expressed enthusiasm about the appointment. “We are pleased to welcome Giancarlo to BeiGene in what continues to be a transformative journey for us, solidifying our position as a top global oncology innovator. Giancarlo brings a wealth of experience and a proven track record in the pharmaceutical industry, which will be instrumental as we continue to grow our presence in Europe.
His leadership and vision are a perfect fit for BeiGene, aligning with our commitment to expanding our global footprint and enhancing our capabilities in this vital region. We look forward to the positive impact his expertise will bring to our team and our work,” said Oyler. BeiGene appoints Mr. Benelli to leverage his experience and leadership as the company expands its operations and impact.
Giancarlo Benelli has over 20 years of experience in the pharmaceutical industry, having held senior leadership roles at leading global companies, including Novartis and AstraZeneca. Most recently, he served as Vice President and Head of Radioligand Therapy International Markets at Novartis, where he oversaw key markets outside the U.S. and Europe, contributing significantly to Novartis’ global oncology portfolio. With his extensive experience in oncology, Mr. Benelli is well-positioned as BeiGene appoints him to lead its European operations during this critical growth phase.
Mr. Benelli expressed his excitement about joining BeiGene at this crucial time in the company’s development. “I am honoured and excited to join BeiGene at such a pivotal point in the company’s growth,” he said. “BeiGene’s dedication to discovering and developing innovative treatments that are both affordable and accessible resonates deeply with my own personal and professional values.
I am eager to connect with more than 800 of our colleagues across Europe to contribute to our shared aspiration of transforming the lives of cancer patients. Together, we will strive to expand our reach and impact in Europe, bringing hope and healing to those who need it most.” By appointing Mr. Benelli, BeiGene aims to enhance its ability to achieve these ambitious goals.
Before his role at Novartis, Mr. Benelli had a successful career at Advanced Accelerator Applications, where he served as General Manager. In this capacity, he was responsible for restructuring the manufacturing, research and development, and commercial organizations following the acquisition of the company by Novartis. His leadership was pivotal in ensuring business continuity and launching Lutathera, a radiopharmaceutical treatment for neuroendocrine tumors, in France and Italy despite the challenges of the post-merger integration. BeiGene appoints leaders like Mr. Benelli to drive such strategic initiatives that will make a meaningful difference in the lives of patients.
Mr. Benelli holds a Medical Doctorate and a Postgraduate Diploma in Thoracic Surgery from the University of Genoa, Italy, as well as a Diploma in Health Economics from the University of York, UK. This strong academic background complements his experience, making him an ideal choice as BeiGene appoints him to lead its efforts in Europe.
About BeiGene:
BeiGene, which plans to rebrand as BeOne Medicines Ltd., is a global leader in oncology committed to discovering, developing, and delivering innovative cancer treatments that are both affordable and accessible to patients worldwide. With a diverse portfolio, BeiGene is advancing its pipeline of novel therapeutics through its internal expertise and strategic collaborations. The company is dedicated to radically improving access to medicines for cancer patients globally. With nearly 11,000 employees across five continents, BeiGene is accelerating the development of cutting-edge therapies that aim to transform cancer treatment and improve the lives of patients worldwide. As the company continues to evolve, it appoints leaders like Giancarlo Benelli to help drive its mission forward.
Please find the related post
